# Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

> **NCT06605599** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 161 (actual)

## Conditions studied

- Bipolar I Disorder
- Bipolar II Disorder

## Interventions

- **DRUG:** ABBV-932
- **DRUG:** Placebo for ABBV-932

## Key facts

- **NCT ID:** NCT06605599
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-15
- **Primary completion:** 2025-11-12
- **Final completion:** 2025-12-10
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06605599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06605599, "Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06605599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*